NCT03905850View on ClinicalTrials.gov

A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

March 29, 2019

Primary Completion Date

July 15, 2019

Study Completion Date

July 15, 2019

Conditions

Healthy VolunteersGrowth Hormone Deficiency

Interventions

DRUG

somapacitan

5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY